|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Moreover, a statistically significant increased risk of the rs3787016 TT genotype was observed among the patients with advanced tumor stage (Ⅲ and Ⅳ), poor histological grade (G3-G4), positive lymph node involvement, positive expression of ER and PR and negative expression of HER-2; rs7463708 GT and GT/GG genotype were associated with decreased risk of breast cancer in the subgroup of patients with postmenopausal status (GT versus (<i>vs.</i>) TT: adjusted OR = 0.67, 95% CI = 0.46-0.99, <i>P</i> = 0.043; GT/GG <i>vs</i>.
|
28607590 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients treated for metastatic BC prior to biopsy had lower CD8 (overall: p = 0.005, HER2+: p = 0.011, TN: p = 0.075).
|
29929548 |
2018 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Deletion of GnT-V (MGAT5), which synthesizes N-glycans with β(1,6)-branched glycans, reduced the compartment of cancer stem cells (CSC) in the her-2 mouse model of breast cancer, leading to delay of tumor onset.
|
25274627 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, elevated expression of Gab1 was positively associated with metastasis in HER2 and TNBC subtypes of BCa.
|
30665442 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In contrast, we observed no association of ERBB2 single nucleotide polymorphism haplotypes with breast cancer predisposition.
|
19336545 |
2009 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
CN hierarchical clustering revealed distinct patterns of gains, losses and complex alterations in HER2- and non-HER2-genes associated with IHC4 breast cancer subtypes.
|
25098819 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Gene status in HER2 equivocal breast carcinomas: impact of distinct recommendations and contribution of a polymerase chain reaction-based method.
|
25323485 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Chromosome 17q is highly susceptible to rearrangement mutations in breast cancer. c-erbB-2 at 17q11.2 approximately q21.1 is frequently amplified, as is a region at 17q22 approximately q24.
|
11408059 |
2001 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the identification of HER2-mutated breast cancer has clinical significance.
|
31351155 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The authors studied sRAGE and RAGE polymorphisms in 120 patients with breast cancer (subdivided based on the clinical stage, histologic grading, expression of hormonal and Her2/neu receptors) and in 92 healthy controls.
|
18058469 |
2007 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Significance of serum tumor necrosis factor-alpha and its combination with HER-2 codon 655 polymorphism in the diagnosis and prognosis of breast cancer.
|
20872355 |
2011 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Women with HER2-postive, hormone receptor-positive breast cancer and one or more mutations in PIK3CA were less likely to benefit from neoadjuvant chemotherapy and HER2-targeted therapies than those without a mutation, according to study results presented on December 12 at the 2013 San Antonio Breast Cancer Symposium in Texas.
|
24501315 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Thirty-six publicly available breast cancer datasets (n = 5715) were subjected to molecular subtyping using five published classifiers (three SSPs and two SCMs) and SCMGENE, the new three-gene (ER, HER2, and AURKA) SCM.
|
22262870 |
2012 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Genome-wide copy number aberrations and HER2 and FGFR1 alterations in primary breast cancer by molecular inversion probe microarray.
|
28125801 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Subtype analysis performed for patient subgroups defined by ER, PR, and HER2 status suggested additional associations of the <i>NOTCH3</i> SNP rs200504060 and the <i>HIF1A</i> SNP rs142179458 with breast cancer risk.
|
28775167 |
2017 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Some of the important mutations include epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) mutations in small cell lung cancer, human epidermal growth factor receptor (HER2) mutation in breast cancer, and BRAF mutation in melanoma.
|
30771009 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay.
|
27461826 |
2016 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
We assessed frequency distributions of the KRAS variant in 415 patients with histologically confirmed breast cancer and 457 controls from Connecticut, USA (study group 1) and association of this variant with breast-cancer subtypes in 690 Irish women with known oestrogen receptor (ER), progesterone receptor (PR), and HER2 statuses, and 360 controls (study group 2).
|
21435948 |
2011 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HER2 germline mutation A270S was identified in 5395 consecutive patients with operable primary breast cancer using direct Sanger sequencing analysis.
|
30175972 |
2018 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The HER2 codon 655 polymorphism may be one of many low-penetrant genes that make a minor contribution to breast cancer, particularly in subgroups of women.
|
12846420 |
2003 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
HER2 polymorphisms were assessed in breast cancer tissue and normal breast tissue using TaqMan assay.
|
27788409 |
2016 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our analysis showed that both MIF and IL-17A were associated with increased risk of breast cancer (OR 3.85 CI 95% 1.98-7.50 and OR 4.51 95% 1.83-11.15, respectively), higher in aggressive subtypes Luminal B, HER2 and TN.
|
31102004 |
2019 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Human epidermal growth factor receptor 2 (HER2 gene) and chromosome 17 polysomy are associated with breast cancer prognosis, chemotherapy and hormone therapy.
|
25119636 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Of the four breast cancer subtypes, the associations of rs12493607 (3p24.1/TGFBR2) with HER-2 overexpression in breast cancer (P = 1.09 × 10(-3)) and rs11075995 (16q12.2/FTO) with basal-like breast cancer (P = 1.64 × 10(-4)) were statistically significant.
|
25007960 |
2014 |
|
Breast Carcinoma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In particular, expression of the d16HER2 splice variant in human HER2-positive BC has a crucial pathobiological function, wherein the absence of sixteen amino acids from the extracellular domain induces the formation of stable and constitutively active HER2 homodimers on the tumor cell surface.
|
31261614 |
2019 |